LLR APC Newsletter October 2024(784 KB) - LMSG/LLR APC newsletters
Date added: 7th Nov 2024
Drug Name | Classification | Clinical Indication | Comments |
---|---|---|---|
Abaloparatide (NEW) | Red | Treating osteoporosis after menopause | |
BETULA VERRUCOSA ALLERGEN EXTRACT (Itulazax®) | Orange | Moderate to severe allergic rhinitis/conjunctivitis caused by Birch pollen |
|
DOXYLAMINE SUCCINATE AND PYRIDOXINE (Xonvea®) | Do not prescribe | Nausea and vomiting in pregnancy | |
Indium 111 Oxinate (NEW) | Red | radiopharmaceutical for platelet and leukocyte studies | |
Latanoprost–netarsudil eye drops (NEW) | Green | Primary open-angle glaucoma or ocular hypertension | |
NICARDIPINE injection (NEW) | Red | Blood pressure reduction in acute intra-cerebral haemorrhage within 6 hours of onset |
Second line agent |
Relugolix (NEW) | Red | For treating hormone sensitive prostate cancer | |
SYSTANE® ULTRA preservative free eye drops (UPDATED) | Yellow | Ocular lubricant |
Evaporative Dry Eye & Meibomian Gland Dysfunction only *Thealipid preservative free eye drops are first choice across LLR |
TADALAFIL (10mg and 20mg) | Green | Erectile dysfunction |
For patients who have not responded to sildenafil or to vardenafil. 10mg and 20mg for PRN dosing. NHS limitations on groups and frequency of prescribing apply. FP10 prescriptions should be endorsed with “SLS“. |
TADALAFIL 5mg | Green | Erectile dysfunction |
Approved for daily administration for individuals requiring more than 4 doses per month. Do not prescribe 2.5mg OD dosing. NHS limitations on groups and frequency of prescribing apply. Fp10 prescriptions must be endorsed with “SLS”. |
TheaLipid eye drops (NEW) | Yellow | Evaporative Dry Eye & Meibomian Gland Dysfunction |
First line for evaporative dry eye & meibomian gland dysfunction only |
Varenicline Tartrate | Grey | Smoking cessation in adults | |
Vibegron (NEW) | Green | Overactive bladder syndrome in adults |
Recent documents from LLR APC and TAS
Date added: 7th Nov 2024
Date added: 6th Nov 2024
Date added: 9th Aug 2024
Version 1 Uploaded January 2024
Date added: 14th Sep 2023
Updated November 2024 Primary Care and LPT only
Date added: 20th Jun 2019
Date added: 1st Jun 2015
Version 3.2 Uploaded October 2024
Date added: 26th May 2015
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more